CLINICAL TRIALS AND OBSERVATIONS Oral 6-mercaptopurine versus oral 6-thioguanine and veno-occlusive disease in children with standard-risk acute lymphoblastic leukemia: report of the Children’s Oncology Group CCG-1952 clinical trial

Abstract

1Division of Hematology-Oncology, Doernbecher Children’s Hospital/Oregon Health & Science University, Portland; 2Division of Hematology-Oncology, Rainbow Babies & Children’s Hospital, Case Western Reserve University, Cleveland, OH; 3Division of Hematology-Oncology, The Children’s Medical Center/Wright State University Boonshoft School of Medicine, Dayton, OH; 4Children’s Oncology Group, Statistical Office, Arcadia, CA; 5Division of Pediatric Hematology-Oncology, CancerCare Manitoba, Winnipeg, MB; 6Division of Hematology-Oncology, C. S. Mott Children’s Hospital/University of Michigan, Ann Arbor; 7Department of Pathology, Ohio State University, Columbus; 8Clinical Cancer Genetics, City of Hope National Medical Center, Duarte, CA; 9Cancer Institute of New Jersey, University of Medicine and Dentistry of New Jersey, New Brunswick; 10St Charles Medical Center, Bend, OR and Oregon Health & Science University, Portland; and 11Division of Hematology-Oncology, Childrens Hospital Los Angeles, CA

11 Figures and Tables

Cite this paper

@inproceedings{Stork2010CLINICALTA, title={CLINICAL TRIALS AND OBSERVATIONS Oral 6-mercaptopurine versus oral 6-thioguanine and veno-occlusive disease in children with standard-risk acute lymphoblastic leukemia: report of the Children’s Oncology Group CCG-1952 clinical trial}, author={Linda C. Stork and Yousif H Matloub and Emmett H. Broxson and Mei K L La and Rochelle Avis Yanofsky and Harland N. Sather and Ray Hutchinson and Nyla A. Heerema and April Deon Sorrell and Margaret A Masterson and Archie Bleyer and Paul S. Gaynon}, year={2010} }